Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06277037 · ClinicalTrials.gov registry record
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
A clinical trial of Long Term Follow-up, sponsored by Arbutus Biopharma Corporation.
- Recruiting
- Registry status
- 50
- Enrollment target
- 18
- Study locations
NCT06277037 is a study of Long Term Follow-up that is actively recruiting participants, run by Arbutus Biopharma Corporation. The registered enrollment target is 50 participants. The trial reports 18 study locations across 6 states.
The verdict
NCT06277037, a study of Long Term Follow-up, is actively recruiting participants, sponsored by Arbutus Biopharma Corporation.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).
Conditions Studied
Interventions
- OTHER Non-interventional
Study Locations (18)
Other
- Fiona Stanley Hospital - Murdoch
- Queen Mary Hospital - Hong Kong
- Arensia Exploratory Medicine Moldova - Chisinau
- Asan Medial Center - Seoul
- Changhua Christian Hospital - Changhua
- Chia-Yi Christian Hospital - Chiayi City
- Kaohsiung Medical University Chung-Ho Memorial Hospital - Kaohsiung City
- E-Da Hospital - Kaohsiung City
- Taichung Veterans General Hospital - Taichung
- Chang Gung Medical Foundation Linkou - Taoyuan District
- University Hospital of Wales, Cardiff - Cardiff
- Royal London Hospital - London
- King's College Hospital - London
California
- Research and Education Inc. - San Diego
Florida
- University of Miami Miller School of Medicine - Miami
New Jersey
- Infectious Disease Care - Hillsborough
Victoria
- The Alfred Hospital - Melbourne
New Territories
- Prince of Wales Hospital - Shatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2029-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06277037
The ClinicalTrials.gov registry entry for NCT06277037 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbutus Biopharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long Term Follow-up appearing as the primary indexed condition, and to 1 intervention - of which Non-interventional is the first listed.
NCT06277037 reports 18 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06277037 about?
NCT06277037 is a clinical study titled "Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)". This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 we...
What is the current status of trial NCT06277037?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-07-11. Estimated completion is 2029-10-30.
What conditions does trial NCT06277037 study?
This clinical trial studies the following conditions: Long Term Follow-up.
What interventions are being tested in trial NCT06277037?
The interventions under investigation include: Non-interventional (OTHER).
Who is sponsoring clinical trial NCT06277037?
This trial is sponsored by Arbutus Biopharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06277037 being conducted?
This trial has 18 study locations across California, Florida, New Jersey, Victoria, New Territories. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.